Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal cancer with a dismal five-year survival rate of 11%. Despite remarkable advancements in cancer therapeutics, PDAC patients rarely benefit from it due to insurmountable treatment resistance. Notably, PDAC is pathologically characteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Sheng-Kai, Jadhao, Mahendra, Liao, Wei-Ting, Chang, Wen-Tsan, Hung, Chun-Tzu, Chiu, Chien-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589289/
https://www.ncbi.nlm.nih.gov/pubmed/36299300
http://dx.doi.org/10.3389/fmolb.2022.1020888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589289/
https://www.ncbi.nlm.nih.gov/pubmed/36299300
http://dx.doi.org/10.3389/fmolb.2022.1020888

Ejemplares similares